South Jordan, Utah-based Merit reported profits of $6.2 million, or 11¢ per share, on sales of $238.3 million for the three months ended March 31, for a 10.0% profit gain on sales growth of 17.4% compared with the same period last year.
Adjusted to exclude one-time items, earnings per share were 37¢, two pennies ahead of Wall Street, where analysts were looking for sales of $236.5 million.
“Our first-quarter results fulfilled our goal of 8% to 10% core growth by landing on the top side of our projection,” founder, chairman & CEO Fred Lampropoulos said in prepared remarks. “Our transition of the Becton, Dickinson deal continues on schedule with some of the acquired products now being built in our facility in Tijuana, Mexico. The entire transition program is scheduled for completion later this year.
“The Cianna transition is complete and sales continue to grow according to our expectations,” Lampropoulos said. “Although the complications of Brexit, consolidation of notified bodies and the new European Medical Device Regulation have slowed new product approvals, we anticipate receiving approval of the Savi Scout for sale in Europe in the near future.”
Merit still expects to post EPS of $1.97 to $2.08 this year on sales of $1.01 billion to $1.03 billion, Lampropoulos said during a conference call with analysts yesterday.
MMSI shares closed up 2.8% yesterday at $59.20 and had gained another 1.1% to $59.83 in pre-market trading today.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.